SEH1L and cancer: The limited prior association of SEH1L, TUBA4A, ZYX, and TCF3 with chemoresistance (Figure 6C), combined with their consistent dysregulation across cancer types (Figure 4B and Figure 5D,F), nominates them as novel and promising biomarker candidates for predicting DOX sensitivity.